News & Events

Projected Growth within Injectable Industry – Symbiosis Foresee Similar Trend

According to Frost & Sullivan’s (2013), Global Pharmaceutical Contract Manufacturing Market – report, injectable drug development will be a main growth driver over the next few years  as the pharmaceutical industry continues to focus on oncology and treatment with cytotoxic drugs in particular.  Symbiosis CEO Colin MacKay said “We are seeing a similar trend.  A large proportion of our customers work within oncology and many are interested in our ability to safely manufacture cytotoxics and ADCs (Antibody Drug Conjugates) for clinical trials”.

Symbiosis specialises in the sterile, GMP manufacture of novel, injectable pharmaceuticals (including cytotoxic, conventional and biologics) for use in clinical trials.

Source: Frost &Sullivan (2013) Injectable Drugs to Drive CMO Growth. [Online] Available at: SocialMedia [Accessed on 12 September 2013]

Get In Touch.

By ticking the box and clicking “Submit” below, you consent to receiving thought leadership, industry news, and invitations by email or other electronic means, which Symbiosis Pharmaceutical Services believes may be of value to you, relevant to your work and tailored to your professional profile and interests. This may include promotional information on products, services and events provided or organised by Symbiosis Pharmaceutical Services. By clicking the "Submit” button, you confirm that the information you have provided above is correct, and you agree to Symbiosis' processing of your personal data, including its transfer internationally and to third parties, in accordance with it's privacy policy.